#160880

MLL-AF9-miR-139 knock out cell line

Cat. #160880

MLL-AF9-miR-139 knock out cell line

Cat. #: 160880

Organism: Mouse

Tissue: Bone Marrow

Disease: Cancer

Model: Cancer Model

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Stefan Erkeland

Institute: Erasmus Medical Center

Tool Details
Target Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: MLL-AF9-miR-139 knock out cell line
  • Alternate name: miR-139
  • Parental cell: Lineage negative bone marrow cells isolated from miR139 KO mice
  • Organism: Mouse
  • Tissue: Bone Marrow
  • Donor: Lineage negative bone marrow cells were isolated from miR139 KO mice and transduced with MLL-AF9.
  • Disease: Cancer
  • Growth properties: Enhanced Proliferation
  • Model: Cancer Model
  • Conditional: No
  • Description: MIR-139 is a critical tumor surpressor in AML
  • Production details: Lineage negative bone marrow cells were isolated from miR139 KO mice and transduced with MLL-AF9.
  • Recommended controls: MIR139 WT, MLL-AF9 cells

Target Details

  • Target: MIR139

Handling

  • Growth medium: As published in Stavast, C.J., van Zuijen, I., Karkoulia, E. et al. The tumor suppressor MIR139 is silenced by POLR2M to promote AML oncogenesis. Leukemia 36, 687â?‚€?‚“700 (2022). https://doi.org/10.1038/s41375-021-01461-5

References

  • Stavast et al. 2022. Leukemia. 36(3):687-700. PMID: 34741119.